Clinical Trial Update: Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lenalidomide (Revlimid) as induction and maintenance therapy for high-risk multiple myeloma has completed, with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Sponsor: Cristina Gasparetto | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2014-04-10